Program Intellectual Property. Genethon hereby grants to Audentes an exclusive (including as to Genethon), royalty-free, fully paid-up, worldwide, sublicenseable license under Genethon’s interest in any Program Intellectual Property for the purpose of making, using, importing, selling, offering for sale and otherwise discovering, researching, developing or commercializing Products.
Appears in 2 contracts
Sources: Collaborative Development Agreement (Audentes Therapeutics, Inc.), Collaborative Development Agreement (Audentes Therapeutics, Inc.)